-
公开(公告)号：US09862760B2
公开(公告)日：2018-01-09
申请号：US15258925
申请日：2016-09-07
申请人： Johanna Abend , Zorica Dragic , Adam Lloyd Feire , Mark Knapp , Steven Kovacs , Elisabetta Traggiai , Lichun Wang , Yongqiang Wang , Danqing Wu , Qilong Wu , Fangmin Xu
发明人： Johanna Abend , Zorica Dragic , Adam Lloyd Feire , Mark Knapp , Steven Kovacs , Elisabetta Traggiai , Lichun Wang , Yongqiang Wang , Danqing Wu , Qilong Wu , Fangmin Xu
CPC分类号： C07K16/084 , A61K39/42 , A61K45/06 , C07K2317/20 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
-
公开(公告)号：US09815901B2
公开(公告)日：2017-11-14
申请号：US14830392
申请日：2015-08-19
申请人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
发明人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , C12N5/078 , C12N5/0783 , A61K39/00 , C07K16/24
CPC分类号： C07K16/2866 , A61K39/0011 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , C07K16/244 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/03 , C07K2319/33 , C12N5/0636
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
-
3.发明申请TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR 审中-公开使用人类抗体BCMA CHIMERIC抗原受体治疗癌症公开(公告)号：US20160046724A1
公开(公告)日：2016-02-18
申请号：US14805193
申请日：2015-07-21
申请人： Jennifer Brogdon , Eugene Choi , Hilmar Erhard Ebersbach , David Glass , Heather Huet , Carl H. June , Joan Mannick , Michael C. Milone , Leon Murphy , Gabriela Plesa , Celeste Richardson , Marco Ruella , Reshma Singh , Yongqiang Wang , Qilong Wu
发明人： Jennifer Brogdon , Eugene Choi , Hilmar Erhard Ebersbach , David Glass , Heather Huet , Carl H. June , Joan Mannick , Michael C. Milone , Leon Murphy , Gabriela Plesa , Celeste Richardson , Marco Ruella , Reshma Singh , Yongqiang Wang , Qilong Wu
IPC分类号： C07K16/30 , C07K14/705 , A61K38/17 , A61K35/12 , A61K39/395
CPC分类号： C07K14/705 , A61K35/12 , A61K38/177 , A61K39/395 , A61P35/00 , C07H21/04 , C07K14/7151 , C07K16/28 , C07K16/2878 , C07K19/00 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/30 , C12N5/00 , C12N15/63
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
摘要翻译： 本发明提供用于治疗与BCMA表达相关的疾病的组合物和方法。 本发明还涉及对编码其的BCMA载体特异的嵌合抗原受体（CAR）和包含BCMA CAR的重组T细胞。 本发明还包括施用表达包含BCMA结合结构域的CAR的经遗传修饰的T细胞的方法。
-
4.发明申请公开(公告)号：US20180118834A1
公开(公告)日：2018-05-03
申请号：US15543688
申请日：2016-01-15
申请人： Jennifer Brogdon , Hilmar Erhard Ebersbach , David Glass , Thomas Huber , Julia Jascur , Carl H. June , Jihyun Lee , Joan Mannick , Michael C. Milone , Leon Murphy , Avery D. Posey , Huijuan Song , Yongqiang Wang , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang , Novartis Pharma AG , NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. , China Novartis Institutes for Biomedical Research , The Trustees of the University of Pennsylvania
发明人： Jennifer Brogdon , Hilmar Erhard Ebersbach , David Glass , Thomas Huber , Julia Jascur , Carl H. June , Jihyun Lee , Joan Mannick , Michael C. Milone , Leon Murphy , Avery D. Posey , Huijuan Song , Yongqiang Wang , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , A61K35/17 , C07K16/30 , A61P35/00 , A61P35/02 , A61K48/00 , C12N15/86
CPC分类号： C07K16/2863 , A61K35/17 , A61K48/0058 , A61K2035/124 , A61P35/00 , A61P35/02 , C07K14/705 , C07K14/7051 , C07K14/70521 , C07K16/28 , C07K16/30 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N15/86 , C12N2740/10043 , C12N2740/15043 , C12N2800/60
摘要： The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
-
公开(公告)号：US20160068601A1
公开(公告)日：2016-03-10
申请号：US14830392
申请日：2015-08-19
申请人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
发明人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
CPC分类号： C07K16/2866 , A61K39/0011 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , C07K16/244 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/03 , C07K2319/33 , C12N5/0636
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
摘要翻译： 本发明提供用于治疗与CD123表达相关的疾病的组合物和方法。 本发明还涉及对CD123特异性的嵌合抗原受体（CAR），编码它的载体和包含CD123 CAR的重组细胞。 本发明还包括施用表达包含CD123结合结构域的CAR的遗传修饰的细胞的方法。
-
6.发明申请公开(公告)号：US20160311917A1
公开(公告)日：2016-10-27
申请号：US15105082
申请日：2014-12-19
申请人： Gregory Beatty , Boris Engels , Neeraja Idamakanti , Carl H. June , Andreas Loew , Huijuan Song , Qilong Wu
发明人： Gregory Beatty , Boris Engels , Neeraja Idamakanti , Carl H. June , Andreas Loew , Huijuan Song , Qilong Wu
IPC分类号： C07K16/30 , C07K14/705 , C07K14/715 , C12N5/0783 , A61K39/395 , A61K48/00 , A61K38/17 , C12N15/85 , A61K31/436 , C07K14/725
CPC分类号： C07K16/30 , A61K31/436 , A61K38/00 , A61K38/1774 , A61K38/1793 , A61K39/0011 , A61K39/39558 , A61K48/0058 , A61K2039/505 , A61K2039/5158 , C07K14/7051 , C07K14/70517 , C07K14/7151 , C07K16/303 , C07K16/3061 , C07K16/3069 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/74 , C12N5/0638 , C12N15/85 , C12N15/86 , C12N2740/15041
摘要： Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
摘要翻译： 提供了用于治疗与间皮素表达相关的疾病的组合物和方法。 还提供了对间皮素特异性的嵌合抗原受体（CAR），编码它的载体和包含间皮素CAR的重组T细胞。 还提供了施用表达包含间皮素结合结构域的CAR的遗传修饰的T细胞的方法。
-
公开(公告)号：US20160311907A1
公开(公告)日：2016-10-27
申请号：US15105074
申请日：2014-12-19
申请人： Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
发明人： Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
IPC分类号： C07K16/28 , A61K35/17 , C12N9/90 , C07K14/705 , C07K14/71 , C07K14/725 , A61K31/436
CPC分类号： C07K16/2863 , A61K31/436 , A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/41 , C07K2319/43 , C07K2319/70 , C12N9/1205 , C12N9/90 , C12Y502/00
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
摘要翻译： 提供了与可调节嵌合抗原受体（RCAR）相关的组合物和方法，其中可以控制RCAR的细胞内信号传导或增殖以优化使用表达RCAR的细胞以提供免疫应答。 例如，RCAR可以包含二聚转换开关，其在二聚化分子的存在下可以将细胞内信号结构域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域或共刺激ECD结构域 。 RCAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。
-
公开(公告)号：US20160051651A1
公开(公告)日：2016-02-25
申请号：US14805075
申请日：2015-07-21
申请人： Jennifer Brogdon , Hilmar Erhard Ebersbach , Saar Gill , David Glass , Julia Jascur , Saad Kenderian , Joan Mannick , Michael C. Milone , Leon Murphy , Celeste Richardson , Reshma Singh , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang
发明人： Jennifer Brogdon , Hilmar Erhard Ebersbach , Saar Gill , David Glass , Julia Jascur , Saad Kenderian , Joan Mannick , Michael C. Milone , Leon Murphy , Celeste Richardson , Reshma Singh , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang
IPC分类号： A61K39/00 , A61K31/7068 , C07K14/705 , A61K45/06 , C07K16/28 , C07K14/725
CPC分类号： A61K39/0011 , A61K31/7068 , A61K35/17 , A61K45/06 , A61K2039/5156 , C07K14/7051 , C07K14/70578 , C07K16/2851 , C07K2317/622 , C07K2319/02 , C07K2319/03
摘要： The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
摘要翻译： 本发明提供了治疗与CLL-1表达相关的疾病的组合物和方法。 本发明还涉及对CLL-1特异性的嵌合抗原受体（CAR），编码它的载体和包含CLL-1 CAR的重组细胞。 本发明还包括施用基因修饰的表达包含CLL-1结合结构域的CAR的细胞的方法。
-
公开(公告)号：US20180334490A1
公开(公告)日：2018-11-22
申请号：US15529246
申请日：2015-12-02
申请人： Jennifer Brogdon , Gregory Beatty , David Glass , Carl H. June , Joan Mannick , Michael Milone , Leon Murphy , Gabriela Plesa , Huijuan Song , Qilong Wu , Novartis AG , The Trustees of the University of Pennsylvania
发明人： Jennifer Brogdon , Gregory Beatty , David Glass , Carl H. June , Joan Mannick , Michael Milone , Leon Murphy , Gabriela Plesa , Huijuan Song , Qilong Wu
IPC分类号： C07K14/725 , A61P35/00 , A61K35/17 , C07K14/705 , C07K16/28 , C07K16/30 , A61K45/06 , A61K38/17 , A61K39/395 , A61K31/675 , A61K31/436 , A61N5/10
CPC分类号： C07K14/7051 , A61K31/436 , A61K31/675 , A61K35/00 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/545 , A61N5/10 , A61N2005/1098 , A61P35/00 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K16/2863 , C07K16/30 , C07K16/3023 , C07K16/303 , C07K16/3061 , C07K16/3069 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C07K2319/70
摘要： The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.
-
公开(公告)号：US20170260268A1
公开(公告)日：2017-09-14
申请号：US15511973
申请日：2015-09-17
申请人： Gregory BEATTY , Boris ENGELS , Neeraja IDAMAKANTI , Carl H JUNE , Andreas LOEW , Michael C. MILONE , Huijuan SONG , Enxiu WANG , Qilong WU
发明人： Gregory Beatty , Boris Engels , Neeraja Idamakanti , Carl H. June , Andreas Loew , Michael Milone , Huijuan Song , Enxiu Wang , Qilong Wu
IPC分类号： C07K16/28 , C07K14/725 , C07K16/30 , C12N5/0783 , A61K35/17 , C07K14/74 , C07K14/705
CPC分类号： C07K16/28 , A61K35/17 , C07K14/705 , C07K14/70503 , C07K14/7051 , C07K14/70535 , C07K14/70539 , C07K14/7056 , C07K14/70596 , C07K16/30 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/74 , C07K2319/02 , C07K2319/03 , C07K2319/70 , C07K2319/74 , C12N5/0636 , C12N2510/00
摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.086 秒)
